JPWO2021155468A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155468A5 JPWO2021155468A5 JP2022548056A JP2022548056A JPWO2021155468A5 JP WO2021155468 A5 JPWO2021155468 A5 JP WO2021155468A5 JP 2022548056 A JP2022548056 A JP 2022548056A JP 2022548056 A JP2022548056 A JP 2022548056A JP WO2021155468 A5 JPWO2021155468 A5 JP WO2021155468A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- atoms
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 94
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 66
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 150000002431 hydrogen Chemical class 0.000 claims description 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 49
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 43
- 125000004429 atom Chemical group 0.000 claims description 40
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 38
- 229910052805 deuterium Inorganic materials 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 32
- 229910005965 SO 2 Inorganic materials 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 21
- 229910020008 S(O) Inorganic materials 0.000 claims description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 20
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000006644 (C2-C6) haloalkynyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 101150020251 NR13 gene Proteins 0.000 claims description 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 2
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 230000003938 response to stress Effects 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 206010011906 Death Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical group [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 5
- 101710085469 CD2 homolog Proteins 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 102100036364 Cadherin-2 Human genes 0.000 description 3
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000871 behavioral problem Toxicity 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- -1 CO 2 R 13 Chemical group 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000014679 binge eating disease Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 206010057342 Onychophagia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000023906 Sexual and Gender disease Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 208000027688 depersonalization disease Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172009A JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969934P | 2020-02-04 | 2020-02-04 | |
| US62/969,934 | 2020-02-04 | ||
| PCT/CA2021/050123 WO2021155468A1 (en) | 2020-02-04 | 2021-02-04 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172009A Division JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513679A JP2023513679A (ja) | 2023-04-03 |
| JPWO2021155468A5 true JPWO2021155468A5 (https=) | 2024-02-07 |
| JP2023513679A5 JP2023513679A5 (https=) | 2024-02-07 |
Family
ID=77199666
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548056A Pending JP2023513679A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2022548057A Pending JP2023513680A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548057A Pending JP2023513680A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US20220024956A1 (https=) |
| EP (2) | EP4100390A4 (https=) |
| JP (5) | JP2023513679A (https=) |
| KR (3) | KR20240023678A (https=) |
| CN (3) | CN115974757A (https=) |
| AU (2) | AU2021217424A1 (https=) |
| BR (2) | BR112022015375A2 (https=) |
| CA (2) | CA3166936A1 (https=) |
| IL (2) | IL295371B1 (https=) |
| MX (2) | MX2022009526A (https=) |
| PH (1) | PH12022551981A1 (https=) |
| WO (2) | WO2021155468A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| CN115867533B (zh) * | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| GB2632056B (en) * | 2020-08-21 | 2025-04-16 | Compass Pathfinder Ltd | Novel psilocin derivatives having prodrug properties |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022115944A1 (en) * | 2020-12-01 | 2022-06-09 | Magicmed Industries Inc. | Carboxylated psilocybin derivatives and methods of using |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| WO2022120181A1 (en) | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| EP4263504A4 (en) * | 2020-12-18 | 2025-05-14 | COMPASS Pathfinder Limited | Modified indole alkaloids for therapeutic uses |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| WO2022155751A1 (en) | 2021-01-22 | 2022-07-28 | Magicmed Industries Inc. | Prenylated psilocybin derivatives and methods of using |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| US20220370413A1 (en) * | 2021-03-06 | 2022-11-24 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| WO2022195011A1 (en) * | 2021-03-18 | 2022-09-22 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| CN117177959A (zh) * | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | 裸头草碱类似物、盐、组合物和使用方法 |
| JP2024511597A (ja) * | 2021-03-18 | 2024-03-14 | サイビン アイアールエル リミテッド | シロシビンの類似体、塩、組成物、及び使用方法 |
| WO2022235531A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Movement disorders |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| US11344564B1 (en) | 2021-08-20 | 2022-05-31 | Lennham Pharmaceuticals, Inc. | Method of treatment based on reduced monoamine oxidase a activity |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| WO2023077245A1 (en) * | 2021-11-08 | 2023-05-11 | Nova Mentis Life Science Corp. | Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| US12404238B2 (en) | 2021-12-10 | 2025-09-02 | Caamtech, Inc. | Psilocybin derivatives |
| JP2024546138A (ja) * | 2021-12-14 | 2024-12-17 | レユニオン ニューロサイエンス，インコーポレイテッド | トリプタミンプロドラッグ |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| WO2023133873A1 (en) * | 2022-01-17 | 2023-07-20 | Nokia Shanghai Bell Co., Ltd. | Configuration for in-x subnetworks |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493544A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE |
| EP4518855A1 (en) * | 2022-05-01 | 2025-03-12 | Short Wave Pharma Inc. | A mucoadhesive film comprising a pharmaceutically active agent and uses thereof |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024055106A1 (en) * | 2022-09-12 | 2024-03-21 | Bionxt Solutions Inc. | Amino acid and carbohydrate psilocin derivatives |
| JP2026501775A (ja) * | 2023-01-05 | 2026-01-16 | リユニオン・ニューロサイエンス、インコーポレイテッド | トリプタミンプロドラッグの薬物動態の改善 |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2024227149A2 (en) * | 2023-04-27 | 2024-10-31 | Atai Therapeutics, Inc. | Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| CN121793958A (zh) * | 2023-06-27 | 2026-04-03 | 帕多瓦大学 | 使用二甲-4-羟色胺磷酸的联合疗法 |
| CN121909189A (zh) | 2023-06-28 | 2026-04-21 | 赛洛私人有限公司 | 用于治疗精神疾病的吡咯并吡啶化合物 |
| AU2024309903A1 (en) | 2023-06-28 | 2026-01-08 | Psylo Pty Ltd | Compounds |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| CN121752545A (zh) * | 2023-11-06 | 2026-03-27 | 宜昌人福药业有限责任公司 | 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途 |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US12310974B1 (en) | 2023-12-19 | 2025-05-27 | Samuel Aballea | Method of treating post-traumatic stress disorder with carpipramine |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1242318A (en) | 1913-12-20 | 1917-10-09 | Sam Brest | Ash sifter and receptacle. |
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US3078214A (en) * | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| GB933286A (en) | 1961-03-23 | 1963-08-08 | Lodge Cottrell Ltd | Improvements in and relating to electro-precipitation |
| CH414639A (de) * | 1961-10-20 | 1966-06-15 | Sandoz Ag | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |
| US3202675A (en) | 1961-10-26 | 1965-08-24 | Sterling Drug Inc | 1-benzyl-2, 5-bis (chloromethyl) pyrrolidine and acid-addition salts thereof |
| BE615395A (https=) | 1962-03-21 | |||
| GB990092A (en) | 1962-10-24 | 1965-04-22 | Roche Products Ltd | Novel indole derivatives and a process for the manufacture thereof |
| US7700612B2 (en) * | 2003-12-23 | 2010-04-20 | Abraxis Bioscience, Llc | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| CN101395164A (zh) | 2006-01-10 | 2009-03-25 | 罗伊·J·于 | N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法 |
| EP2014662A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| EP2254865A1 (en) * | 2008-02-11 | 2010-12-01 | Organix, Inc. | Indole compounds and methods of use thereof |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2464227A4 (en) * | 2009-08-10 | 2013-02-20 | Galenea Corp | COMPOUNDS AND METHODS OF USE |
| EP3082819B1 (en) * | 2013-12-20 | 2020-06-17 | Signal Pharmaceuticals, LLC | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| WO2016161138A1 (en) | 2015-03-31 | 2016-10-06 | Stamets Paul Edward | Antiviral activity from medicinal mushrooms and their active constituents |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| CZ307719B6 (cs) | 2015-12-31 | 2019-03-20 | Vysoká škola chemicko-technologická v Praze | Použití derivátu tryptaminu |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3077053A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Methods and compositions for inhibition of stat3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| AU2020215150B8 (en) | 2019-01-30 | 2025-07-03 | Diamond Therapeutics Inc. | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| JP2023514559A (ja) | 2020-02-05 | 2023-04-06 | イエール ユニバーシティ | 頭痛障害の幻覚剤処置 |
| WO2021226092A1 (en) | 2020-05-04 | 2021-11-11 | Trustees Of Tufts College | Synthetic lipid-like materials for brain delivery |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US20220169606A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Compositions and compounds for bioanalysis |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US20220168274A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Parenteral Formulation |
| CN115867533B (zh) | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| GB2632056B (en) | 2020-08-21 | 2025-04-16 | Compass Pathfinder Ltd | Novel psilocin derivatives having prodrug properties |
| WO2022043227A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| US12343328B2 (en) * | 2020-12-09 | 2025-07-01 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
| EP4263504A4 (en) | 2020-12-18 | 2025-05-14 | COMPASS Pathfinder Limited | Modified indole alkaloids for therapeutic uses |
-
2021
- 2021-02-04 PH PH1/2022/551981A patent/PH12022551981A1/en unknown
- 2021-02-04 IL IL295371A patent/IL295371B1/en unknown
- 2021-02-04 MX MX2022009526A patent/MX2022009526A/es unknown
- 2021-02-04 EP EP21750671.6A patent/EP4100390A4/en active Pending
- 2021-02-04 BR BR112022015375A patent/BR112022015375A2/pt unknown
- 2021-02-04 JP JP2022548056A patent/JP2023513679A/ja active Pending
- 2021-02-04 CN CN202310101242.9A patent/CN115974757A/zh active Pending
- 2021-02-04 WO PCT/CA2021/050123 patent/WO2021155468A1/en not_active Ceased
- 2021-02-04 IL IL295364A patent/IL295364B1/en unknown
- 2021-02-04 KR KR1020247004116A patent/KR20240023678A/ko active Pending
- 2021-02-04 BR BR112022015377A patent/BR112022015377A2/pt unknown
- 2021-02-04 CN CN202180026581.4A patent/CN115427395A/zh active Pending
- 2021-02-04 AU AU2021217424A patent/AU2021217424A1/en active Pending
- 2021-02-04 JP JP2022548057A patent/JP2023513680A/ja active Pending
- 2021-02-04 CN CN202180026575.9A patent/CN115397810A/zh active Pending
- 2021-02-04 MX MX2022009527A patent/MX2022009527A/es unknown
- 2021-02-04 AU AU2021215811A patent/AU2021215811A1/en active Pending
- 2021-02-04 KR KR1020227030603A patent/KR20220137081A/ko active Pending
- 2021-02-04 CA CA3166936A patent/CA3166936A1/en active Pending
- 2021-02-04 WO PCT/CA2021/050125 patent/WO2021155470A1/en not_active Ceased
- 2021-02-04 CA CA3166933A patent/CA3166933A1/en active Pending
- 2021-02-04 EP EP21751268.0A patent/EP4100391A4/en active Pending
- 2021-02-04 KR KR1020227030616A patent/KR20220137083A/ko active Pending
- 2021-07-28 US US17/387,883 patent/US20220024956A1/en active Pending
- 2021-07-28 US US17/387,845 patent/US11427604B2/en active Active
-
2022
- 2022-05-13 US US17/743,718 patent/US11597738B2/en active Active
- 2022-06-06 US US17/833,341 patent/US11591353B2/en active Active
- 2022-12-12 US US18/079,617 patent/US12054505B2/en active Active
-
2023
- 2023-01-27 US US18/102,359 patent/US20230167141A1/en not_active Abandoned
- 2023-02-15 US US18/109,890 patent/US20230203070A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024015076A patent/JP2024054193A/ja active Pending
- 2024-05-30 US US18/678,114 patent/US12378266B2/en active Active
- 2024-12-16 US US18/982,452 patent/US20250388611A1/en active Pending
-
2025
- 2025-10-10 JP JP2025172009A patent/JP2026010068A/ja active Pending
- 2025-12-09 JP JP2025243928A patent/JP2026053405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021155468A5 (https=) | ||
| JPWO2021155470A5 (https=) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| RU2119484C1 (ru) | Тропонзамещенный фенилоксазолидинон или его фармацевтически приемлемые соли или гидраты | |
| JPWO2021155467A5 (https=) | ||
| EP3472152A1 (en) | Heterocyclic compounds as antibacte rials | |
| JP2009538910A5 (https=) | ||
| RU2637309C2 (ru) | Способ получения соединений тиенопиримидина | |
| JP2015523406A5 (https=) | ||
| JP2015514073A (ja) | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用 | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| TW201321364A (zh) | 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途 | |
| JP2019511546A (ja) | 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピリジニルアミノ）プロパニル］アリールカルボキサミド | |
| JP3521214B2 (ja) | ４，５−ジヒドロイソオキサゾリルアルキルピペラジン誘導体とその製造方法並びにドーパミン拮抗剤 | |
| JP6368776B2 (ja) | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 | |
| JP2025502712A (ja) | シクロプロピル化合物 | |
| AU2021262281A1 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| RU2007106970A (ru) | Новые хромен-2-оновые производные и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| JP2021520415A5 (https=) | ||
| JP2024542881A (ja) | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 | |
| JP2024540583A (ja) | Ｋｖ７．２エンハンサーとしてのピリジン化合物 | |
| JPWO2022120475A5 (https=) | ||
| JP3520177B2 (ja) | セロトニン５−ｈｔ３受容体部分活性薬 | |
| JPWO2022183288A5 (https=) | ||
| JP2009537598A (ja) | 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用 |